

**CENTER FOR DRUG EVALUATION AND RESEARCH**

**Application Number: NDA 19726/S24**

**APPROVAL LETTER**

**ORIGINAL**

NDA 19-726/S-024  
NDA 20-578/S-003

**JUL 27 1998**

Zeneca Pharmaceuticals, Inc.  
Attention: Ms. Kimi Denoble  
Assistant Manager, Marketed Products Group  
1800 Concord Pike  
PO Box 15437  
Wilmington, DE 19850-5437

Dear Ms. DeNoble:

Please refer to your supplemental new drug applications dated August 11, 1997, received August 12, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Zoladex® (goserelin acetate) 3.6 mg Depot, and 10.8 mg Depot.

We acknowledge receipt of your submissions dated August 28, 1997, and April 9, June 12, July 21, and 24, 1998. The user fee goal date for these applications is August 12, 1998.

These supplemental new drug applications provide for the use of Zoladex® (goserelin acetate) 3.6 mg and 10.8 mg Depots in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C) carcinoma of the prostate.

We have completed the review of these supplemental applications, as amended, and have concluded that adequate information has been presented to demonstrate that the drug products are safe and effective for use as recommended in the agreed upon labeling text. Accordingly, these supplemental applications are approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the submitted draft labeling for the package insert dated July 21, 1998 (3.6 mg Depot) and the package insert dated July 24, 1998 (10.8 mg Depot). Marketing the products with FPL that is not identical to the approved labeling text may render the products misbranded and unapproved new drugs.

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed, to each application. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, these submissions should be designated "FPL for approved supplemental NDAs 19-726/S-024 and 20-578/S-003." Approval of these submissions by FDA is not required before the labeling is used.

If additional information relating to the safety or effectiveness of this drug becomes available before we receive the final printed labeling, revision of that labeling may be required.

In addition, please submit three copies of the introductory promotional materials that you propose to use for these products. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package inserts directly to:

NDA 19-726/S-024

NDA 20-578/S-003

Page 2

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Healthcare Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Alvis Dunson, Project Manager, at (301) 827- 4260.

Sincerely,

*LSI*

7/27/98

Lisa D. Rarick, M.D.  
Director  
Division of Reproductive and Urologic Drug Products  
Office of Drug Evaluation II  
Center for Drug Evaluation and Research

Drafted by: ADunson/July 1, 1998

Concurrences:

NAME	TITLE	SIGNATURE	DATE
Lana L. Pauls, M.P.H.	Chief, Project Management Staff	/S/	7/27/98
Mark Hirsch, M.D.	Medical Officer	/S/ /S/	7/27/98
Daniel Shames, M.D.	Acting Medical Team Leader	/S/	7/27/98
Moo-Jhong Rhee, Ph.D.	Chemistry Team Leader	/S/	7/27/98
Alex Jordan, Ph.D.	Pharmacology Team Leader	/S/	7/27/98
<sup>for</sup> Angelica Dorantes, Ph.D.	Pharmacokinetics Team Leader	/S/	7/27/98
Joy Mele, M.S.	Acting Statistical Team Leader	/S/	7/27/98
Marianne Mann, M.D.	Deputy Director	/S/	7/27/98
Lisa Rarick, M.D.	Division Director	/S/	7/27/98

cc:  
 Archival NDAs 19-726, 20-578  
 HFD-580/Div. Files  
 HFD-580/ADunson/MHirsch/DShames/MRhee/AJordan  
 HFD-580/ADorantes/KMeaker/MMann/LRarick/LPauls  
 HF-2/MedWatch (with labeling)  
 HFD-002/ORM (with labeling)  
 HFD-102/ADRA (with labeling)  
 HFD-40/DDMAC (with labeling)  
 HFD-613/OGD (with labeling)  
 HFD-95/DDMS (with labeling)  
 HFD-820/DNDC Division Director  
 DISTRICT OFFICE

Drafted by: ADunson/July 1, 1998  
 filename: N19726AP.24

APPROVAL (AP)